| ID Source | ID |
|---|---|
| PubMed CID | 9832431 |
| CHEMBL ID | 2218898 |
| SCHEMBL ID | 18732840 |
| MeSH ID | M0506937 |
| Synonym |
|---|
| fe 200 440 |
| fe200 440 |
| barusiban [inn] |
| 285571-64-4 |
| c(sup 4.6),s(sup 1)-cyclo(n-(3-sulfanylpropanoyl)-d-tryptophyl-l-isoleucyl-l-alloisoleucyl-l-asparaginyl-l-2-aminobutanoyl-n-methyl-l-ornithinol) |
| unii-ux33i93gls |
| c4.6,s1-cyclo(n-(3-sulfanylpropanoyl)-d-tryptophyl-l-isoleucyl-l-alloisoleucyl-l-asparaginyl-l-2-aminobutanoyl-n-methyl-l-ornithinol) |
| barusiban |
| ux33i93gls , |
| fe-200440 |
| CHEMBL2218898 |
| SCHEMBL18732840 |
| DB12292 |
| Q19596024 |
| gtpl10890 |
| (4s,7s,10s,13s,16r)-n-[(2s)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(2r)-butan-2-yl]-16-(1h-indol-3-ylmethyl)-n-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide |
| c4.6,s1-cyclo[n-(3-sulfanylpropanoyl)-d-tryptophyl-l-isoleucyl-l-alloisoleucyl-l-asparaginyl-l-2-aminobutanoyl-n-methyl-l-ornithinol] |
| CS-0615345 |
| HY-P3516 |
Barusiban is an oxytocin antagonist under development for potential use as tocolytic in preterm-labor patients.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Barusiban is an oxytocin antagonist under development for potential use as tocolytic in preterm-labor patients." | ( Barusiban, a selective oxytocin receptor antagonist: placental transfer in rabbit, monkey, and human†. Helmer, H; Knöfler, M; Petricevic, L; Reinheimer, TM; Saleh, L, 2020) | 2.72 |
| "Barusiban is a new selective, potent, and long-acting OXT receptor antagonist." | ( Barusiban, an effective long-term treatment of oxytocin-induced preterm labor in nonhuman primates. Bee, WH; Chellman, GJ; Meyer, JK; Reinheimer, TM; Resendez, JC, 2006) | 2.5 |
| "Barusiban is a selective OT antagonist which has reached clinical development." | ( Barusiban suppresses oxytocin-induced preterm labour in non-human primates. Reinheimer, TM, 2007) | 2.5 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Barusiban-treated animals delivered normally following end of treatment (ca." | ( Barusiban suppresses oxytocin-induced preterm labour in non-human primates. Reinheimer, TM, 2007) | 2.5 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 4 (44.44%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (44.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||